Refine by
Critical Patient Articles & Analysis
88 news found
While approved targeted agents are available to treat several types of oncogenic mutations, patients whose cancers harbor oncogene amplification typically do not derive the same benefit. ...
The HFSA Optimal Medical Therapy in Heart Failure (OMT-HF) program can help your patients achieve their best outcomes. An estimated 6.5 million Americans have heart failure (HF). This year alone another 960,000 will likely be diagnosed with this condition. Chances are several of your patients are in this group. Are they receiving the optimal medical therapy (OMT), that helps them achieve ...
Applying induced pluripotent stem cell (iPSC) technology, patient-cell derived 3D micro tissues exhibiting hereditary cardiac diseases are mass-produced in micro wells. ...
The Ivenix Infusion System from Fresenius Kabi is a large volume infusion pump supported by a management system specifically designed to simplify each step of infusion delivery and help eliminate unnecessary work while informing patient care teams. “To meaningfully impact medication safety, we reimagined the infusion process from beginning to end,” said Susan ...
Demonstrated 98% NPV1 to Identify COVID-19 Patients at Risk for Severe Illness Study Data Indicate Symphony IL-6 Test Could be a Rapid and Precise Diagnostic Platform for Near-Patient Management of Critical Care Bluejay Diagnostics, Inc. ...
The Company expects to initiate the trial by the end of 2022 and anticipates dosing the first patient in the trial in the first quarter of 2023. GBM is an aggressive, deadly, and treatment-resistant type of malignant brain tumor, affecting approximately 13,000 newly diagnosed patients each year in the United States. Few treatment options are available for ...
ByCervoMed
He explained that these kinds of technologies will allow people to be referred to physicians or nurses for further treatment or diagnosis, or even summon help for critical patients. “These wearable devices are going to be able to extend the capabilities of a physician beyond where they are physically,” Hansen explained. ...
Thomas Rand, MD from the Klinik Floridsdorf Vienna, Austria presented the initial clinical results from the safety and performance study of REVA’s MOTIV sirolimus-eluting bioresorbable scaffold in patients with Critical Limb Ischemia (CLI) and BTK lesions. Prof. Rand presented the study at the Leipzig Interventional Course (LINC) 2022. ...
” The first study1 (abstract #04729) was presented in a poster session and evaluated whether SeptiCyte® RAPID could be used as a triage tool for COVID-19 patients at a hospital2 in France. Results demonstrated SeptiCyte® RAPID’s ability to distinguish between COVID-19 patients showing higher extents of lung damage as defined by lung CT scans ...
“We are focused on finding the right treatment for cancer patients and together we believe we can help accelerate that goal.” “Collaborating with xCures is a great example of how Prognos is solving for disconnected, siloed data that cannot interoperate and leaves an incomplete view of the patient, said Sundeep Bhan, founder and CEO of Prognos. ...
ByxCures
“It is exciting to join a team that is designing and delivering products engineered to address critical patient needs with physician driven solutions.” Amsel Medical’s SCureClamp™ with Interdigitation Occlusion Technology (iDOT™) is designed to easily and securely close vessels – veins, arteries, and tubular structures ...
“Now more than ever, it is critical that we equip and empower clinicians with the safest, most effective, and connected infusion equipment possible,” said Pete Allen, senior vice president, Nutrition and Infusion Therapy, Fresenius Kabi USA. ...
Despite affecting over 400 million people around the globe, rare diseases have largely been overlooked by traditional drug discovery methods. This is because traditional model often prioritise disease areas where there is a greater understanding of the basic underlying biology and which, in turn, generally come from the larger patient populations associated with more common diseases. This is part ...
Its flagship product, CytoSorb®, is approved in the European Union with distribution in more than 70 countries around the world as an extracorporeal cytokine adsorber designed to reduce the “cytokine storm” or “cytokine release syndrome” seen in common critical illnesses that may result in massive inflammation, organ failure and ...
I believe the benefits of our innovative blood purification technology will make a positive impact on the lives of treated patients throughout the region,” said Whittemore. Dr. Christian Steiner, Executive Vice President, Sales and Marketing of CytoSorbents stated, “As we establish a direct sales team in the UK and Ireland, we are excited to work more closely with ...
The US business serves a vital role, providing life and limb-saving medicines to healthcare professionals treating patients with critical conditions.” Thomas most recently served as Senior Vice President & General Manager for Medical Therapeutics at Endo Pharmaceuticals. He previously worked as Vice-President of CNS Patient and ...
Its flagship product, CytoSorb®, is approved in the European Union with distribution in more than 70 countries around the world as an extracorporeal cytokine adsorber designed to reduce the “cytokine storm” or “cytokine release syndrome” seen in common critical illnesses that may result in massive inflammation, organ failure and ...
“This acquisition supports our strategy to build a portfolio of products that improves the standard of care for patients suffering from critical and rare conditions.” Xermelo will be commercially available from SERB outside the US and Japan starting in July 2022. About carcinoid syndrome Carcinoid syndrome is a rare condition that affects about a ...
Biotres is the Company’s revolutionary technology that represents the future of Remote Patient Monitoring and the delivery of real-time diagnostic data. It serves as a three-lead device designed to continuously record electrocardiogram (ECG) data for early detection of cardiac arrhythmias, disrupting the conventional one-lead patch Holter monitor which takes longer analysis ...
The Edinburgh Royal Infirmary will evaluate suspected lung cancer patients while Groningen Medical Centre will study EMI-137 in early stage pancreatic cancer. ...